[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f11c2zfvswzzyz":5},{"data":4},[],{"data":6,"error":10},{"id":7,"documentId":8,"slug":9,"name":9,"proprietary_name":10,"non_proprietary_name":10,"is_proprietary":10,"active_ingredient":10,"administration_route":10,"available_strength":10,"dosage_form":10,"dose_schedule":10,"drug_unit":10,"is_available_generically":10,"mechanism_of_action":10,"overdosage":10,"warning":10,"species":11,"citations":12,"dose_schedules":23,"available_strengths":35,"label_statements":40,"drug_classes":56,"specialties":62,"medical_conditions":63,"animal_species":64},1850,"wy5l1iescx9a39iytcm2pkko","atinvicitinib",null,[],[13,19],{"source":14,"licence":15,"source_url":16,"harvested_by":17,"retrieved_at":18},"EMA centrally authorised medicines","EMA reuse with attribution","https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fdocuments\u002Freport\u002Fmedicines-output-medicines-report_en.xlsx","load-reference-corpus.cjs","2026-09-07",{"source":20,"licence":21,"source_url":22,"harvested_by":17,"retrieved_at":18},"UK VMD PID","OGL v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Fdownloads\u002Fvmd_productinformationdatabase.xlsx",[24,30],{"id":25,"dose_text":26,"species":27,"administration_route":28,"limitation":10,"source_label":29},13665,"Administer orally, once daily, with food, at a dose of 0.36 to 0.54 mg atinvicitinib\u002Flb (0.8 to 1.2 mg atinvicitinib\u002Fkg) body weight.","Dogs","Oral","Numelvi™",{"id":31,"dose_text":32,"species":10,"administration_route":33,"limitation":10,"source_label":34},13666,"DOSAGE AND ADMINISTRATION:\nNUMELVI should be administered orally, once daily, at a dose of 0.36 to 0.54 mg atinvicitinib\u002Flb (0.8 to 1.2 mg atinvicitinib\u002Fkg) body weight according to the Dosing Table below.\nNUMELVI should be administered with food.\nDosing Table\nBody Weight\nRanges (lb)\nBody Weight\nRanges (kg)\nNumber of Tablets to be Administered\n4.8 mg tablets\n7.2 mg tablets\n21.6 mg tablets\n31.6 mg tablets\n4.4 - 6.5\n2 - 2.9\n0.5\n6.6 - 9.5\n3 - 4.3\n0.5\n9.6 - 13.3\n4.4 - 6\n1\n13.4 - 19.9\n6.1 - 9\n1\n20 - 29.8\n9.1 - 13.5\n0.5\n29.9 - 42.6\n13.6 - 19.3\n0.5\n42.7 - 58.4\n19.4 - 26.5\n1\n58.5 - 87\n26.6 - 39.5\n1\n87.1 - 118.9\n39.6 - 54\n1.5\n119 - 174.2\n54.1 - 79\n2\n≥ 174.3\n≥79.1\nAdminister the appropriate combination of tablet strengths","ORAL","Numelvi™ (atinvicitinib tablets)",[36],{"id":37,"strength_text":38,"dosage_form":39,"proprietary_name":29,"species":27,"source_label":29},11883,"4.8, 7.2, 21.6, or 31.6 mg of atinvicitinib per tablet","Tablet",[41,45,48,52],{"id":42,"kind":43,"statement":44,"species":27,"limitation":10,"source_label":29},20039,"indication","For the control of pruritus associated with allergic dermatitis in dogs 6 months of age and older.",{"id":46,"kind":43,"statement":47,"species":10,"limitation":10,"source_label":34},20040,"INDICATIONS:\nNUMELVI is indicated for the control of pruritus associated with allergic dermatitis in dogs 6 months of age and older.",{"id":49,"kind":50,"statement":51,"species":10,"limitation":10,"source_label":34},20041,"warning","CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.",{"id":53,"kind":54,"statement":55,"species":10,"limitation":10,"source_label":34},20042,"adverse_reaction","In a masked field study assessing effectiveness and safety of NUMELVI for the control of pruritus associated with allergic dermatitis in dogs, 144 NUMELVI-treated dogs and 144 placebo-treated dogs were evaluated for safety for up to 28 days. Adverse reactions seen during the field study are summarized in Table 1 below.\nTable 1. Adverse Reactions through Day 28\nAdverse Reaction\nNUMELVI (N=144)\nNumber of dogs (%)\nPlacebo (N=144)\nNumber of dogs (%)\nVomiting or nausea\n10 (6.9%)\n6 (4.2%)\nOtitis externa\n9 (6.3%)\n8 (5.6%)\nHematuria (without urinary tract infection)\n7 (4.9%)\n6 (4.2%)\nAnorexia\n6 (4.2%)\n5 (3.5%)\nBacterial skin infection\n6 (4.2%)\n10 (6.9%)\nDiarrhea\n6 (4.2%)\n15 (10.4%)\nCrystalluria\n5 (3.5%)\n2 (1.4%)\nLethargy\n5 (3.5%)\n5 (3.5%)\nUrinary tract infection\n5 (3.5%)\n5 (3.5%)\nUpset stomach, including flatulence, retching, and bloating\n3 (2.1%)\n0\nNeurological disorder (e.g., tremors, ataxia)\n2 (1.4%)\n1 (0.7%)\nOcular discharge\n2 (1.4%)\n1 (0.7%)\nCoughing\n1 (0.7%)\n0\nGranuloma\n1 (0.7%)\n0\nIncreased urination\n1 (0.7%)\n0\nAbnormal hematology results likely related to NUMELVI administration included leukopenia, neutropenia, eosinopenia, monocytopenia, and lymphocytosis.\nAbnormal serum chemistry results likely related to NUMELVI administration included increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), and symmetric dimethylarginine (SDMA), and hypercholesterolemia.\nThree NUMELVI-treated dogs withdrew from the study early due to an adverse reaction, two of which were considered likely related to NUMELVI treatment (i.e., diarrhea). Two placebo-treated dogs also withdrew from the study early due to an adverse reaction (i.e., diarrhea).",[57],{"id":58,"documentId":59,"slug":60,"name":61},968,"kuytl7ouqgwa3kt55y2t1kwc","agents-for-dermatitis-excluding-corticosteroids","Agents for dermatitis, excluding corticosteroids",[],[],[]]